What is Juno Therapeutics'stock price today?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO." What is Juno Therapeutics' stock price today? One share of JUNO stock can currently be purchased for approximately $86.96.
What is Juno Therapeutics'(Juno) business model?
Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer.
How much did Juno raise from its IPO?
(JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.
Who bought Juno Therapeutics?
CelgeneA few months later, in January 2018, Celgene acquired Juno in a $9 billion deal. The New Jersey-based biotech company continues to operate Juno's Seattle R&D space and its manufacturing facility in nearby Bothell, Wash. Giovanni Caforio, Bristol-Myers Squibb CEO.
Is Juno part of BMS?
Juno Therapeutics, Inc. is a wholly owned subsidiary of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.
Is Juno publicly traded?
Juno Therapeutics, Inc. is offering shares of common stock. This is our initial public offering and no public market currently exists for our shares.
What does Juno Therapeutics do?
Juno Therapeutics, Inc. is an integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer.
What happened to Bristol Myers contingent value rights?
Can I sell my CVR? No, all BMS CVRs have expired and are no longer eligible for payment since the FDA's approval of liso-cel did not occur by December 31, 2020. The BMS CVRs will no longer trade on the NYSE. For individual investors, please call our information agent, EQ Shareowner Services at 1-833-503-4131.
Who founded Juno?
Juno co-founders Rick Klausner, former global health director of the Bill & Melinda Gates Foundation, and Fred Hutch investigator Stan Riddell are co-founders of Lyell Immunopharma, which has operations in the Seattle area and went public in a $425 million IPO this summer.
Who owns Juno biotech?
Bristol Myers SquibbJuno Therapeutics / Parent organizationThe Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2021, it had a total revenue of $46.4 billion. Wikipedia
Where is Juno Therapeutics located?
Seattle, WashingtonJuno Therapeutics is located in Seattle, Washington, United States .
When was Juno founded?
Information on Juno became public in February 2016, following an unheralded and unannounced beta testing of a software app to 2000 drivers in New York City. Information leaked, and the company began granting interviews by 16 February 2016. Juno had intended to operate without press for several months.
How were Juno Therapeutics' earnings last quarter?
Juno Therapeutics Inc (NASDAQ:JUNO) released its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS f...
Who are Juno Therapeutics' key executives?
Juno Therapeutics' management team includes the following people: Howard H. Pien , Independent Chairman of the Board (Age 59) Hans Edgar Bishop...
What other stocks do shareholders of Juno Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (CELG) , (KITE)...
When did Juno Therapeutics IPO?
(JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15...
What is Juno Therapeutics' stock symbol?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."
What is Juno Therapeutics' stock price today?
One share of JUNO stock can currently be purchased for approximately $86.96.
What is Juno Therapeutics' official website?
The official website for Juno Therapeutics is www.junotherapeutics.com .
How can I contact Juno Therapeutics?
Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States . The biopharmaceutical company can be reac...
0.0 Analyst's Opinion
Juno Therapeutics has received 496 “outperform” votes. (Add your “outperform” vote.)
How were Juno Therapeutics' earnings last quarter?
Juno Therapeutics Inc (NASDAQ:JUNO) released its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.07.
What other stocks do shareholders of Juno Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (CELG), (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), TherapeuticsMD (TXMD), Incyte (INCY), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI).
What is Juno Therapeutics' stock symbol?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."
What is Juno Therapeutics' stock price today?
One share of JUNO stock can currently be purchased for approximately $86.96.
What is Juno Therapeutics' official website?
The official website for Juno Therapeutics is www.junotherapeutics.com.
About JUNO
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies.
Stats
Download the Public app to invest in this stock with any amount of money. Enter your cell phone number below to get started.
Rating
What analysts on recommend for this stock, on a scale from 1 (buy) to 5 (sell).
Who is the CEO of Juno?
Image source: Getty Images. Here's what Juno's CEO Hans Bishop had to say about the deal: "The people at Juno channel their passion for science and patients toward a common goal of finding cures by creating cell therapies that help people live longer, better lives.
Who is the CEO of Celgene?
And here is Celgene's CEO Mark Alles' commentary on the acquisition: "The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers.
What happened
Juno Therapeutics ( JUNO ), a clinical-stage oncology company, continued its unrelenting rally this year by tacking on another $5 billion to its market cap in November, according to data from S&P Global Market Intelligence. Juno's market capitalization has thus risen by a whopping $4.6 billion since the start of 2017.
So what
Juno is attempting to overcome the first-mover advantage of both Gilead Sciences and Novartis by bringing a safer, and more potent, CAR-T therapy to market. Whether Juno can achieve this all-important goal remains to be seen, but JCAR017's early stage data are on the right track.
Now what
Juno is pushing JCAR017 as hard as it can in an effort to catch up to Gilead and Novartis. As a result, the biotech is aiming to have JCAR017 approved for advanced NHL by as early as 2018. And if this rather aggressive timeline holds, Juno should be able to push even higher next year.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
